Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) - Pipeline Review, H2 2012

Global Markets Direct, December 2012, Pages: 33

Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE). Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE).
- A review of the Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 3
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) 7
Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Therapeutics under Development by Companies 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Therapeutics – Products under Development by Companies 12
Companies Involved in Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Therapeutics Development 13
Amgen Inc. 13
Rigel Pharmaceuticals, Inc. 14
Celgene Corporation 15
Astion Pharma A/S 16
Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) – Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
AMG-811 - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
tanzisertib - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
CC-11050 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
R-salbutamol sulphate - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
R-333 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Therapeutics – Drug Profile Updates 28
Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Therapeutics - Dormant Products 30
Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) – Product Development Milestones 31
Featured News & Press Releases 31
Sep 05, 2012: Rigel Pharma Initiates Phase II Clinical Study With R333 For Discoid Lupus 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33

List of Tables
Number of Products Under Development for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), H2 2012 7
Products under Development for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Mid Clinical Stage Development, H2 2012 10
Comparative Analysis by Early Clinical Stage Development, H2 2012 11
Products under Development by Companies, H2 2012 12
Amgen Inc., H2 2012 13
Rigel Pharmaceuticals, Inc., H2 2012 14
Celgene Corporation, H2 2012 15
Astion Pharma A/S, H2 2012 16
Assessment by Monotherapy Products, H2 2012 17
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Stage and Molecule Type, H2 2012 21
Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Therapeutics – Drug Profile Updates 28
Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Therapeutics – Dormant Products 30

List of Figures
Number of Products under Development for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), H2 2012 7
Products under Development for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Mid Clinical Stage Products, H2 2012 10
Early Clinical Stage Products, H2 2012 11
Assessment by Monotherapy Products, H2 2012 17
Assessment by Route of Administration, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Molecule Type, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 21

Customers who bought this item also bought

• Cutaneous Lupus Erythematosus - Pipeline Review, H2 2012
• Systemic Lupus Erythematosus - Pipeline Review, H2 2012
• Systemic Lupus Erythematosus (Event Driven)
• Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018
• Global Systemic Lupus Erythematosus Pipeline Capsule - 2013
• Systemic Lupus Erythematosus Partnering 2007-2013
• Global Musculoskeletal Disorders Drug Pipeline Capsule – 2012
• Rheumatology Therapeutics Market to 2018 - Increasing Uptake of Benlysta, Uloric, Krystexxa, and the Launch of Oral Tofacitinib to Spur Growth
• R&D Trends: Systemic Lupus Erythematosus - Benlysta's FDA approval provides hope for disease treatment, future trial design, and other pipeline candidates
• Emerging Therapies to Treat Lupus Erythematosus